If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

3rd April, 2023

ADPro substudy methodology manuscript published

Home > News > ADPro substudy methodology manuscript published

We are pleased to announce that ‘Functional imaging in asthma and COPD: design of the NOVELTY ADPro substudy’ has been published in ERJ Open Research.

The article describes the design and rationale of the Advanced Diagnostic Profiling (ADPro) substudy of NOVELTY, which is being conducted in a subset of approximately 180 patients from two primary care sites in the UK. The ADPro substudy will use hyperpolarised Xenon-129 magnetic resonance imaging (¹²⁹Xe MRI) and physiological and metabolic measurements to explore structural and functional changes in the lungs and their association with phenotypes and endotypes in patients with asthma and/or COPD. Patterns of ventilation, gas transfer, acinar dimensions and small airways dysfunction will be examined.

Findings from the ADPro substudy should increase understanding of the phenotypes and endotypes of patients with asthma and/or COPD, and will help to inform a precision-based medicine approach to patient care in future clinical practice.

The full article is available here.

Read a summary of this article, and other NOVELTY publications and presentations here.

19 PARTICIPATING COUNTRIES^a

~12,000 ENROLLED PATIENTS^a

84% OF PATIENTS HAVE SPIROMETRY DATA^b

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study